---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Specific populations questions"
description: "Specific populations questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Do adults 70 and older have lower immune responses to Prevnar 20? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Specific populations questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Specific populations questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Specific populations](https://www.evicenter.com/medical-information/prevnar-20/specific-populations).

## Specific populations

<a id="prevnar20-older-adults-response"></a>

### Do adults 70 and older have lower immune responses to Prevnar 20?

> “Of the total number of Prevnar 20 recipients 18 years of age and older evaluated for safety in the 3 main clinical trials (N=4263), 26.7% (n=1138) were 65 years of age and older and 1.7% (n=72) were 80 years of age and older [see Clinical Studies (14.2)].”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Of%20the%20total%20number%20of,older%20%5Bsee%20Clinical%20Studies%20%2814.2%29%5D.)

> “Prevnar 20 recipients 70 through 79 years of age and ≥80 years of age had lower OPA GMTs for all pneumococcal serotypes compared to Prevnar 20 recipients 18 through 49 years, 50 through 59, and 60 through 64 years of age [see Clinical Studies (14.1)].”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Prevnar%2020%20recipients%2070%20through,age%20%5Bsee%20Clinical%20Studies%20%2814.1%29%5D.)

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Indication](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines)
